Incyte Reports 71% Response Rate in Phase 1 Colorectal Cancer Trial
Incyte reported a 71% response rate for INCA33890 in combination in a phase 1 colorectal cancer trial.
Incyte reported a 71% response rate for INCA33890 in combination in a phase 1 colorectal cancer trial.